How Can Pharma Manufacturers Improve Collaboration with Specialty Pharmacies?

At the 2018 National Association of Specialty Pharmacy (NASP) Annual Meeting and Educational Conference,

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discussed how collaboration with manufacturers can help specialty pharmacies prepare from a patient services and distribution perspective.

Transcript

"What we’re seeing is a compressed approval time. If you go back to 2017, you had 7 to 14 approved out of phase 1 or phase 2 data. From the manufacturer’s perspective, they’re on a condensed timeline. We have Commissioner Gottlieb hoping to get these therapies reviewed much more quickly. So what that means from a specialty pharmacy and patient services and distribution perspective is we need to begin talking about these solutions for services and distribution much, much earlier in the process.

Five years ago, we were looking at agents in phase 3. Now, we need to being those discussions in phase 2, very early phase 2, as we begin to see the results of these trials. We have some agents that are going straight from phase 1 phase 3, which is phenomenal. Being prepared and ready is key."